5.45 USD
+0.02 (+0.37%)
5.45 USD
0 (0%)
Taking everything into account, CTKB scores 3 out of 10 in our fundamental rating. CTKB was compared to 57 industry peers in the Life Sciences Tools & Services industry. The financial health of CTKB is average, but there are quite some concerns on its profitability. CTKB has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year CTKB has reported negative net income.
CTKB had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: CTKB reported negative net income in multiple years.
Of the past 5 years CTKB 4 years had a positive operating cash flow.
1.2 Ratios
CTKB has a Return On Assets (-2.59%) which is comparable to the rest of the industry.
CTKB's Return On Equity of -3.39% is in line compared to the rest of the industry. CTKB outperforms 56.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.59% | ||
| ROE | -3.39% | ||
| ROIC | N/A |
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CTKB has a better Gross Margin (53.46%) than 66.67% of its industry peers.
CTKB's Gross Margin has improved in the last couple of years.
CTKB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
2. Health
2.1 Basic Checks
CTKB does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTKB has less shares outstanding than it did 1 year ago.
CTKB has less shares outstanding than it did 5 years ago.
CTKB has a worse debt/assets ratio than last year.
2.2 Solvency
CTKB has an Altman-Z score of 4.36. This indicates that CTKB is financially healthy and has little risk of bankruptcy at the moment.
CTKB has a Altman-Z score of 4.36. This is in the better half of the industry: CTKB outperforms 71.93% of its industry peers.
CTKB has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, CTKB is in the better half of the industry, outperforming 70.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.36 |
ROIC/WACCN/A
WACC10.93%
2.3 Liquidity
CTKB has a Current Ratio of 5.17. This indicates that CTKB is financially healthy and has no problem in meeting its short term obligations.
CTKB has a Current ratio of 5.17. This is amongst the best in the industry. CTKB outperforms 80.70% of its industry peers.
A Quick Ratio of 4.48 indicates that CTKB has no problem at all paying its short term obligations.
CTKB's Quick ratio of 4.48 is amongst the best of the industry. CTKB outperforms 80.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.17 | ||
| Quick Ratio | 4.48 |
3. Growth
3.1 Past
The earnings per share for CTKB have decreased strongly by -25.00% in the last year.
CTKB shows a decrease in Revenue. In the last year, the revenue decreased by -2.18%.
Measured over the past years, CTKB shows a very strong growth in Revenue. The Revenue has been growing by 28.19% on average per year.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)-2.18%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%1.54%
3.2 Future
The Earnings Per Share is expected to decrease by -54.99% on average over the next years. This is quite bad
CTKB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.99% yearly.
EPS Next Y-338.6%
EPS Next 2Y-109.43%
EPS Next 3Y-54.99%
EPS Next 5YN/A
Revenue Next Year-3.27%
Revenue Next 2Y1.08%
Revenue Next 3Y3.61%
Revenue Next 5Y4.99%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CTKB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTKB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A cheap valuation may be justified as CTKB's earnings are expected to decrease with -54.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-109.43%
EPS Next 3Y-54.99%
5. Dividend
5.1 Amount
CTKB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.45
+0.02 (+0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners63.25%
Inst Owner Change0%
Ins Owners9.26%
Ins Owner Change1.68%
Market Cap696.84M
Revenue(TTM)196.83M
Net Income(TTM)-12.82M
Analysts78.18
Price Target5.87 (7.71%)
Short Float %5.86%
Short Ratio5.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.64%
Min EPS beat(2)25.3%
Max EPS beat(2)43.98%
EPS beat(4)3
Avg EPS beat(4)1.29%
Min EPS beat(4)-96.08%
Max EPS beat(4)43.98%
EPS beat(8)5
Avg EPS beat(8)133.03%
EPS beat(12)6
Avg EPS beat(12)68.3%
EPS beat(16)10
Avg EPS beat(16)81.62%
Revenue beat(2)0
Avg Revenue beat(2)-1.98%
Min Revenue beat(2)-3.53%
Max Revenue beat(2)-0.43%
Revenue beat(4)0
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-5.11%
Max Revenue beat(4)-0.43%
Revenue beat(8)2
Avg Revenue beat(8)-2.52%
Revenue beat(12)3
Avg Revenue beat(12)-4.77%
Revenue beat(16)5
Avg Revenue beat(16)-3.49%
PT rev (1m)9.52%
PT rev (3m)12.2%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-225%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.54 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.84 | ||
| P/tB | 2.02 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.22
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS1.54
BVpS2.96
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.59% | ||
| ROE | -3.39% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.46% | ||
| FCFM | N/A |
ROA(3y)-1.05%
ROA(5y)-0.34%
ROE(3y)-1.33%
ROE(5y)-0.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.56%
GM growth 5Y2.26%
F-ScoreN/A
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 48.2% | ||
| Cap/Sales | 2.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.17 | ||
| Quick Ratio | 4.48 | ||
| Altman-Z | 4.36 |
F-ScoreN/A
WACC10.93%
ROIC/WACCN/A
Cap/Depr(3y)175.97%
Cap/Depr(5y)227.57%
Cap/Sales(3y)3.46%
Cap/Sales(5y)3.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y-338.6%
EPS Next 2Y-109.43%
EPS Next 3Y-54.99%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.18%
Revenue growth 3Y16.13%
Revenue growth 5Y28.19%
Sales Q2Q%1.54%
Revenue Next Year-3.27%
Revenue Next 2Y1.08%
Revenue Next 3Y3.61%
Revenue Next 5Y4.99%
EBIT growth 1Y-34.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.26%
EBIT Next 3Y41.52%
EBIT Next 5Y33.94%
FCF growth 1Y24.52%
FCF growth 3Y331.22%
FCF growth 5YN/A
OCF growth 1Y-197.86%
OCF growth 3Y76.32%
OCF growth 5YN/A
CYTEK BIOSCIENCES INC / CTKB FAQ
What is the ChartMill fundamental rating of CYTEK BIOSCIENCES INC (CTKB) stock?
ChartMill assigns a fundamental rating of 3 / 10 to CTKB.
What is the valuation status for CTKB stock?
ChartMill assigns a valuation rating of 0 / 10 to CYTEK BIOSCIENCES INC (CTKB). This can be considered as Overvalued.
How profitable is CYTEK BIOSCIENCES INC (CTKB) stock?
CYTEK BIOSCIENCES INC (CTKB) has a profitability rating of 2 / 10.
How financially healthy is CYTEK BIOSCIENCES INC?
The financial health rating of CYTEK BIOSCIENCES INC (CTKB) is 6 / 10.